Keywords: actelion, gets, 145m, upfront, gsk, part, almorexant

Actelion gets $145M upfront from GSK as part of almorexant marketing accord

Article | 21 July 2008

Print This

Actelion will receive an upfront payment of 150.0 million Swiss francs ($145.3 million) from UK drug major GlaxoSmithKline as part of an ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in